These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 38802821)

  • 1. Immune cell patterns before and after neoadjuvant immune checkpoint blockade combined with chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.
    Zheng DD; Li YY; Yuan XY; Lu JL; Zhang MF; Fu J; Zhang CZ
    BMC Cancer; 2024 May; 24(1):649. PubMed ID: 38802821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor microenvironment biomarkers predicting pathological response to neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell carcinoma: post-hoc analysis of a single center, phase 2 study.
    Feng T; Li Q; Zhu R; Yu C; Xu L; Ying L; Wang C; Xu W; Wang J; Zhu J; Huang M; Xu C; Jin J; Zhang X; Lu T; Yang Y; Zhu C; Chen Q; Su D
    J Immunother Cancer; 2024 Aug; 12(8):. PubMed ID: 39209452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Definitive chemoradiotherapy induces T-cell-inflamed tumor microenvironment in unresectable locally advanced esophageal squamous cell carcinoma.
    Habu T; Kumagai S; Bando H; Fujisawa T; Mishima S; Kotani D; Nakamura M; Hojo H; Sakashita S; Kinoshita T; Yano T; Mitsunaga S; Nishikawa H; Koyama S; Kojima T
    J Gastroenterol; 2024 Sep; 59(9):798-811. PubMed ID: 38819498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to neoadjuvant immune checkpoint inhibitors and chemotherapy in Chinese patients with esophageal squamous cell carcinoma: the role of tumor immune microenvironment.
    Wang X; Ling X; Wang C; Zhang J; Yang Y; Jiang H; Xin Y; Zhang L; Liang H; Fang C; Zheng D; Zhu J; Ma J
    Cancer Immunol Immunother; 2023 Jun; 72(6):1619-1631. PubMed ID: 36583750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma.
    Park S; Joung JG; Min YW; Nam JY; Ryu D; Oh D; Park WY; Lee SH; Choi Y; Ahn JS; Ahn MJ; Park K; Sun JM
    J Immunother Cancer; 2019 May; 7(1):128. PubMed ID: 31097034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spatial Distribution and Predictive Significance of Dendritic Cells and Macrophages in Esophageal Cancer Treated With Combined Chemoradiotherapy and PD-1 Blockade.
    Ma X; Guo Z; Wei X; Zhao G; Han D; Zhang T; Chen X; Cao F; Dong J; Zhao L; Yuan Z; Wang P; Pang Q; Yan C; Zhang W
    Front Immunol; 2021; 12():786429. PubMed ID: 35046943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diffusion-weighted MRI and
    Xu X; Sun ZY; Wu HW; Zhang CP; Hu B; Rong L; Chen HY; Xie HY; Wang YM; Lin HP; Bai YR; Ye Q; Ma XM
    Radiat Oncol; 2021 Jul; 16(1):132. PubMed ID: 34281566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemoradiotherapy combined with sequential perioperative toripalimab in locally advanced esophageal squamous cell cancer.
    Xu X; Sun Z; Liu Q; Zhang Y; Shen L; Zhang C; Lin H; Hu B; Rong L; Chen H; Wang X; Zhao X; Bai YR; Ye Q; Ma X
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38458635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Residual tumor characteristics of esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy.
    Tang H; Jiang D; Zhang S; Zeng Z; Tan L; Hou Y; Wang Q; ; Wang H; Zhu J; Shen Y; Yin J; Ge D
    J Thorac Cardiovasc Surg; 2021 Dec; 162(6):1632-1641. PubMed ID: 33268125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of perioperative immune checkpoint inhibitor therapy for locally advanced esophageal squamous cell carcinoma.
    Kadono T; Yamamoto S; Kato K
    Future Oncol; 2024; 20(28):2097-2107. PubMed ID: 38861290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA-A
    Zhang D; Jiang D; Jiang L; Ma J; Wang X; Xu X; Chen Z; Jiang M; Ye W; Wang J; Meng W; Qiu W; Hou Y; Huang J; Jiao Y; Liu Y; Liu Z
    Br J Cancer; 2024 Jul; 131(1):184-195. PubMed ID: 38762674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of genome and immunogenome in esophageal squamous cell carcinomas driven by neoadjuvant chemoradiotherapy.
    Weng Z; Mai Z; Yuan J; Liu Q; Deng F; Yang H; Ling Y; Xie X; Lin X; Lin T; Chen J; Wei X; Luo K; Fu J; Wen J
    Int J Cancer; 2024 Dec; 155(11):2021-2035. PubMed ID: 39081132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival benefit and spatial properties of tertiary lymphoid structures in esophageal squamous cell carcinoma with neoadjuvant therapies.
    Huang H; Zhao G; Wang T; You Y; Zhang T; Chen X; Dong J; Gong L; Shang X; Cao F; Tang P; Jiang H; Wang P; Pang Q; Yan C; Zhang W
    Cancer Lett; 2024 Oct; 601():217178. PubMed ID: 39142497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impacts of neoadjuvant chemoradiotherapy on the immune landscape of esophageal squamous cell carcinoma.
    Wen J; Fang S; Hu Y; Xi M; Weng Z; Pan C; Luo K; Ling Y; Lai R; Xie X; Lin X; Lin T; Chen J; Liu Q; Fu J; Yang H
    EBioMedicine; 2022 Dec; 86():104371. PubMed ID: 36434949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 expression, CD8+ and CD4+ lymphocyte rate are predictive of pathological complete response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic esophagus.
    Fassan M; Cavallin F; Guzzardo V; Kotsafti A; Scarpa M; Cagol M; Chiarion-Sileni V; Maria Saadeh L; Alfieri R; Castagliuolo I; Rugge M; Castoro C; Scarpa M
    Cancer Med; 2019 Oct; 8(13):6036-6048. PubMed ID: 31429521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma.
    Xu L; Wei XF; Li CJ; Yang ZY; Yu YK; Li HM; Xie HN; Yang YF; Jing WW; Wang Z; Kang XZ; Zhang RX; Qin JJ; Xue LY; Bi N; Chen XK; Li Y
    Front Immunol; 2022; 13():1052542. PubMed ID: 36466925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma.
    He W; Leng X; Mao T; Luo X; Zhou L; Yan J; Peng L; Fang Q; Liu G; Wei X; Wang K; Wang C; Zhang S; Zhang X; Shen X; Huang D; Yi H; Bei T; She X; Xiao W; Han Y
    Oncologist; 2022 Feb; 27(1):e18-e28. PubMed ID: 35305102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of neoadjuvant immunotherapy and lymphocyte subset predictors in locally advanced esophageal squamous cell carcinoma: A retrospective study.
    Wang R; Wen S; Du X; Xia J; Hu B; Zhang Y; Zhou G; Jiang F; Lu X; Zhu M; Xu X; Shen B
    Cancer Med; 2024 Sep; 13(17):e70228. PubMed ID: 39275896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma.
    Sasaki K; Uchikado Y; Omoto I; Arigami T; Osako Y; Noda M; Okumura H; Maemura K; Higashi R; Yoshiura T; Natsugoe S
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):581-587. PubMed ID: 30623230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spatial proteomic profiling elucidates immune determinants of neoadjuvant chemo-immunotherapy in esophageal squamous cell carcinoma.
    Wu C; Zhang G; Wang L; Hu J; Ju Z; Tao H; Li Q; Li J; Zhang W; Sheng J; Hou X; Hu Y
    Oncogene; 2024 Sep; 43(37):2751-2767. PubMed ID: 39122893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.